Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
NCT05162443 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS
Last updated 2025-08-26
Summary
The objective of this EAP is to provide expanded access of adagrasib (MRTX849) to patients with previously treated advanced solid tumors harboring a KRAS G12C mutation.
Conditions
- Advanced Cancer
- Metastatic Cancer
- Malignant Neoplasm
Interventions
- DRUG
-
adagrasib (MRTX849)
adagrasib (MRTX849) will be administered orally twice daily in a continuous regimen
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab
NCT02518958 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
NCT06364696 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)
NCT03234712 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
NCT03600883 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Expanded Access to ABT-414
NCT03123952 ·Status: NO_LONGER_AVAILABLE
-
RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)
NCT02801097 ·Status: TERMINATED ·Phase: PHASE1
-
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors
NCT00591682 ·Status: SUSPENDED ·Phase: PHASE1
-
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
NCT06403436 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation
NCT05480865 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])
NCT04835714 ·Status: TERMINATED ·Phase: PHASE1
-
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
NCT02365662 ·Status: TERMINATED ·Phase: PHASE1
-
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
NCT02073994 ·Status: COMPLETED ·Phase: PHASE1
-
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
NCT05485974 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Expanded Access to ABBV-CLS-484
NCT06188975 ·Status: AVAILABLE
-
Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy
NCT02412462 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors
NCT06797336 ·Status: RECRUITING ·Phase: PHASE1
-
First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation
NCT04006301 ·Status: COMPLETED ·Phase: PHASE1
-
AVID100 in Advanced Epithelial Carcinomas
NCT03094169 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
NCT07196644 ·Status: RECRUITING ·Phase: PHASE2
-
Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors
NCT01122199 ·Status: COMPLETED ·Phase: PHASE1
-
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
NCT05898399 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03071757 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
NCT06884618 ·Status: RECRUITING ·Phase: PHASE1